Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ILK_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ILK_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ILK_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ILK_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ILK_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ILK_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00507752 | Thyroid | PTC | positive regulation of dendrite morphogenesis | 22/5968 | 37/18723 | 4.92e-04 | 3.23e-03 | 22 |
GO:00613873 | Thyroid | PTC | regulation of extent of cell growth | 52/5968 | 110/18723 | 5.20e-04 | 3.37e-03 | 52 |
GO:0071356111 | Thyroid | PTC | cellular response to tumor necrosis factor | 96/5968 | 229/18723 | 8.24e-04 | 5.10e-03 | 96 |
GO:004206315 | Thyroid | PTC | gliogenesis | 121/5968 | 301/18723 | 1.30e-03 | 7.41e-03 | 121 |
GO:003806113 | Thyroid | PTC | NIK/NF-kappaB signaling | 63/5968 | 143/18723 | 1.45e-03 | 8.12e-03 | 63 |
GO:004519710 | Thyroid | PTC | establishment or maintenance of epithelial cell apical/basal polarity | 24/5968 | 44/18723 | 1.52e-03 | 8.49e-03 | 24 |
GO:00434918 | Thyroid | PTC | protein kinase B signaling | 88/5968 | 211/18723 | 1.59e-03 | 8.81e-03 | 88 |
GO:003508810 | Thyroid | PTC | establishment or maintenance of apical/basal cell polarity | 26/5968 | 49/18723 | 1.68e-03 | 9.20e-03 | 26 |
GO:006124510 | Thyroid | PTC | establishment or maintenance of bipolar cell polarity | 26/5968 | 49/18723 | 1.68e-03 | 9.20e-03 | 26 |
GO:007207316 | Thyroid | PTC | kidney epithelium development | 60/5968 | 136/18723 | 1.78e-03 | 9.66e-03 | 60 |
GO:001481212 | Thyroid | PTC | muscle cell migration | 50/5968 | 110/18723 | 1.93e-03 | 1.04e-02 | 50 |
GO:003030718 | Thyroid | PTC | positive regulation of cell growth | 71/5968 | 166/18723 | 1.98e-03 | 1.06e-02 | 71 |
GO:00434057 | Thyroid | PTC | regulation of MAP kinase activity | 75/5968 | 177/18723 | 2.04e-03 | 1.09e-02 | 75 |
GO:0070527111 | Thyroid | PTC | platelet aggregation | 33/5968 | 67/18723 | 2.24e-03 | 1.18e-02 | 33 |
GO:009028712 | Thyroid | PTC | regulation of cellular response to growth factor stimulus | 120/5968 | 304/18723 | 2.87e-03 | 1.42e-02 | 120 |
GO:000176316 | Thyroid | PTC | morphogenesis of a branching structure | 81/5968 | 196/18723 | 3.20e-03 | 1.57e-02 | 81 |
GO:00720067 | Thyroid | PTC | nephron development | 61/5968 | 142/18723 | 3.49e-03 | 1.69e-02 | 61 |
GO:00149095 | Thyroid | PTC | smooth muscle cell migration | 44/5968 | 97/18723 | 3.65e-03 | 1.76e-02 | 44 |
GO:00488144 | Thyroid | PTC | regulation of dendrite morphogenesis | 32/5968 | 67/18723 | 4.75e-03 | 2.22e-02 | 32 |
GO:190122213 | Thyroid | PTC | regulation of NIK/NF-kappaB signaling | 49/5968 | 112/18723 | 5.42e-03 | 2.49e-02 | 49 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ILK | SNV | Missense_Mutation | | c.903N>A | p.Met301Ile | p.M301I | Q13418 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
ILK | SNV | Missense_Mutation | | c.1096G>A | p.Glu366Lys | p.E366K | Q13418 | protein_coding | tolerated(0.14) | benign(0.066) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ILK | SNV | Missense_Mutation | rs752302392 | c.62N>G | p.Asp21Gly | p.D21G | Q13418 | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ILK | SNV | Missense_Mutation | | c.539N>C | p.Gly180Ala | p.G180A | Q13418 | protein_coding | tolerated(1) | benign(0.003) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
ILK | SNV | Missense_Mutation | novel | c.606T>G | p.Asn202Lys | p.N202K | Q13418 | protein_coding | tolerated(0.11) | benign(0.212) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
ILK | SNV | Missense_Mutation | rs752932911 | c.239N>A | p.Arg80His | p.R80H | Q13418 | protein_coding | tolerated(0.49) | benign(0.017) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | | US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine | | |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | | US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine | | |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | inhibitor | 249565796 | | |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | | US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide | | |